Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
enGene Therapeutics Inc. has a significant shareholder group associated with Acorn Bioventures reporting beneficial ownership of its common shares. Anders Hove, through his control of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, reports beneficial ownership of 3,357,282 common shares, representing 5.0% of enGene’s common stock.
Acorn Bioventures, L.P. reports beneficial ownership of 1,410,059 shares (2.1%), while Acorn Bioventures 2, L.P. reports 1,947,223 shares (2.9%). Each Acorn general partner entity reports the same respective share amounts with shared voting and dispositive power, and no sole voting or dispositive power. Percentages are based on 66,989,466 common shares outstanding as of June 9, 2026.
Shares outstanding66,989,466 sharesCommon stock outstanding as of June 9, 2026
Anders Hove beneficial ownership3,357,282 shares (5.0%)Beneficial ownership of enGene common shares
Acorn Bioventures, L.P. ownership1,410,059 shares (2.1%)Beneficial ownership of enGene common shares
Acorn Bioventures 2, L.P. ownership1,947,223 shares (2.9%)Beneficial ownership of enGene common shares
Shared voting power (Anders Hove)3,357,282 sharesShares over which Anders Hove has shared voting power
Key Terms
beneficially own, shared voting power, shared dispositive power, percent of class, +1 more
5 terms
beneficially ownfinancial
"may be deemed to beneficially own the shares of Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting powerfinancial
"Shared Voting Power 3,357,282.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 3,357,282.00"
percent of classfinancial
"Percent of class: The percentages set forth herein are calculated"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
limited partnershipfinancial
"are both Delaware limited partnerships"
A limited partnership is a legal business structure with two types of partners: at least one general partner who runs the business and bears full legal responsibility, and one or more limited partners who contribute money, share profits, and have liability capped at their investment. For investors, it matters because it separates control from financial exposure — like putting money into a store without managing it — and affects how returns, risks, taxes and transferability of ownership are handled.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of enGene Therapeutics (ENGN) does Anders Hove beneficially own?
Anders Hove beneficially owns 5.0% of enGene Therapeutics’ common shares, representing 3,357,282 shares. This ownership is reported through his role as Manager of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
How many enGene Therapeutics (ENGN) shares does Acorn Bioventures, L.P. report owning?
Acorn Bioventures, L.P. reports beneficial ownership of 1,410,059 common shares of enGene Therapeutics, equal to 2.1% of the outstanding common stock, based on 66,989,466 shares outstanding as of June 9, 2026.
What is the reported stake of Acorn Bioventures 2, L.P. in enGene Therapeutics (ENGN)?
Acorn Bioventures 2, L.P. reports beneficial ownership of 1,947,223 common shares of enGene Therapeutics, representing 2.9% of the company’s common stock, calculated using 66,989,466 shares outstanding as of June 9, 2026.
What total share count is used to calculate ownership percentages in this enGene (ENGN) Schedule 13G?
Ownership percentages are calculated using 66,989,466 common shares outstanding as of June 9, 2026, as reported in enGene Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
Do the Acorn entities have sole or shared voting power over enGene Therapeutics (ENGN) shares?
The Acorn entities report 0 shares with sole voting or dispositive power and only shared voting and shared dispositive power over their enGene Therapeutics common shares, reflecting control shared through the Acorn general partner entities and Anders Hove.
Where are the Acorn reporting persons for enGene Therapeutics (ENGN) based?
The Acorn reporting persons list their principal business office at 420 Lexington Avenue, Suite 2626, New York, New York 10170. The Acorn funds and general partners are organized in Delaware, and Anders Hove is a citizen of the United States.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
enGene Therapeutics Inc.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
29286M105
(CUSIP Number)
07/20/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29286M105
1
Names of Reporting Persons
ACORN BIOVENTURES, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,410,059.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,410,059.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,410,059.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
29286M105
1
Names of Reporting Persons
ACORN CAPITAL ADVISORS GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,410,059.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,410,059.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,410,059.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
29286M105
1
Names of Reporting Persons
ACORN BIOVENTURES 2, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,947,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,947,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,947,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
29286M105
1
Names of Reporting Persons
Acorn Capital Advisors GP 2, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,947,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,947,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,947,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
29286M105
1
Names of Reporting Persons
Anders Hove
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,357,282.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,357,282.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,357,282.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
enGene Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA, H4R 2P1.
Item 2.
(a)
Name of person filing:
Acorn Bioventures, L.P.
Acorn Capital Advisors GP, LLC
Acorn Bioventures 2, L.P.
Acorn Capital Advisors GP2, LLC
Anders Hove
(b)
Address or principal business office or, if none, residence:
420 Lexington Avenue, Suite 2626, New York, New York 10170
(c)
Citizenship:
Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.
(d)
Title of class of securities:
Common Shares
(e)
CUSIP Number(s):
29286M105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
(b)
Percent of class:
The percentages set forth herein are calculated based upon 66,989,466 shares of Common Stock outstanding as of June 9, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 filed with the Securities and Exchange Commission on June 15, 2026..
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, L.P. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.
(ii) Shared power to vote or to direct the vote:
Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
(iii) Sole power to dispose or to direct the disposition of:
NA
(iv) Shared power to dispose or to direct the disposition of:
NA
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
